4-iodo-benzo[1,2,5]oxadiazole | 51294-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: 4-iodo-benzo[1,2,5]oxadiazole
• 英文别名: 4-Jodbenzofurazan；4-Iodo-2,1,3-benzoxadiazole
• CAS: 51294-39-4
• 化学式: C₆H₃IN₂O
• 分子量: 246.007
• InChiKey: BKUNEYOPVOCCEE-UHFFFAOYSA-N

物化性质

• 沸点：
  282.9±32.0 °C(Predicted)
• 密度：
  2.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-碘-2,3-二硝基-苯 在 sodium azide 作用下， 以 乙二醇 为溶剂， 生成 4-iodo-benzo[1,2,5]oxadiazole
  参考文献：
  名称：

  Di Nunno,L. et al., Journal of the Chemical Society. Perkin transactions I, 1973, p. 1954 - 1955

  摘要：

  DOI：

文献信息

• Heteroaryl sulfonamides and CCR2
  申请人：ChemoCentryx, Inc.

  公开号：EP2354126A1

  公开（公告）日：2011-08-10

  A compound of the formula (I), or a salt thereof: where Ar is selected from the group consisting of substituted or unsubstituted C6-10 aryl and substituted or unsubstituted 5- to 10-membered heteroaryl; R1 is selected from the group consisting of hydrogen, unsubstituted C1 alkyl, substituted or unsubstituted C3-8 alkyl, substituted or unsubstituted C2-6alkenyl, substituted or unsubstituted C2-6 alkynyl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; Y1 is selected from the group consisting of -CR2a-, -N-, and -N+(O)--; Y2 is selected from the group consisting of -CR2b-, -N-, and -N+(O)--; Y3 is selected from the group consisting of -CR2c-, -N-, and -N+(O)--; R2a, R2b, and R2c are each independently selected from the group consisting of hydrogen, halogen, -CN, -C(O)R3, -CO2R, -C(O)NR3R4, -OR3, -OC(O)R3, -OC(O)NR3R4, -SR3, -S(O)R3, -S(O)2R3, -S(O)2NR3R4, -NO2, -NR3R4, -NR3C(O)R4, -NR3C(O)OR4, - NR3S(O)2R4, -NR3C(O)NR4R5, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl; R3, R4, and R5 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; R3 and R4, R4 and R5 or R3 and R5 may, together with the atoms to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered ring; Y4 is selected from the group consisting of -N- and -N+(O)--; L is selected from the group consisting of a bond, -O-, -S-, -S(O)-, S(O)2-, -CR6R7-, - NR8-, -C(O)- and -NR8C(O)-; R6 and R7 are each independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6alkynyl, -CN, -OR9, -NR10R11, -S(O)R9, and -S(O)2R9; R6 and R7 may, together with the carbon atom to which they are attached, form substituted or unsubstituted C3-8 cycloalkyl or substituted or unsubstituted 3- to 10-membered heterocyclic ring; R9 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; R10 and R11 are each independently selected from the group consisting of substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted C2-8 alkenyl, and substituted or unsubstituted C2-8alkynyl; R10 and R11 of -NR10R11 may, together with the nitrogen, form a substituted or unsubstituted C3-8 cycloalkyl or substituted or unsubstituted 3- to 10-membered heterocyclyl; R8 is selected from the group consisting of hydrogen, C(O)R12, S(O)2R12, CO2R12, substituted or unsubstituted C1-8alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; R12 is selected from the group consisting of substituted or unsubstituted C1-8alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted 3- to 1 0-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl; Z1 is selected from the group consisting of substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted 3- to 10-membered heterocyclyl, and -NR13R14; R13 and R14 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted (61-4 alkyl)-(C6-10 aryl), and substituted or unsubstituted (C1-4 alkyl)-(5- to 10-membered heteroaryl); R13 and R14 may, together with the nitrogen, form a substituted or unsubstituted 4-, 5-, 6-, or 7-membered heterocyclyl with the proviso that compounds of formula CC are excluded: where X14 is selected from the group consisting of -Cl, -NO2, -OCH3, -CH3, -NHC(O)CH3, and -CH2CH2-(phenyl); R65 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-4 alkyl, and substituted or unsubstituted -SO2(phenyl); and R60 is selected from the group consisting of -NR61CH2CH2OR62, - NR61CH2CH2NR63R64, -NR61CH2CH2SR62, where R61 is selected from the group consisting of hydrogen and substituted or unsubstituted phenyl; R62 is selected from the group consisting of substituted or unsubstituted phenyl, and substituted or unsubstituted C1-4alkyl; and R63 and R64 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted -SO2(phenyl), -C(O)CH3, -C(O)C(O)OH, and -C(O)2C(CH3)3.

  本发明涉及式(I)的化合物或其盐： 其中： - Ar选自取代或未取代的C6-10芳基和取代或未取代的5-10元杂芳基； - R1选自氢、未取代的C1烷基、取代或未取代的C3-8烷基、取代或未取代的C2-6烯基、取代或未取代的C2-6炔基，以及取代或未取代的3-10元杂环基； - Y1、Y2和Y3各自独立地选自-CR2a-、-N-和-N+ (O)--； - R2a、R2b和R2c各自独立地选自氢、卤素、-CN、-C(O)R3、-CO2R、-C(O)NR3R4、-OR3、-OC(O)R3、-OC(O)NR3R4、-SR3、-S(O)R3、-S(O)2R3、-S(O)2NR3R4、-NO2、-NR3R4、-NR3C(O)R4、-NR3C(O)OR4、-NR3S(O)2R4、-NR3C(O)NR4R5，取代或未取代的C1-8烷基、取代或未取代的C2-8烯基、取代或未取代的C2-8炔基、取代或未取代的3-10元杂环基、取代或未取代的C6-10芳基，以及取代或未取代的5-10元杂芳基； - R3、R4和R5各自独立地选自氢、取代或未取代的C1-8烷基、取代或未取代的C2-8烯基、取代或未取代的C2-8炔基、取代或未取代的C6-10芳基、取代或未取代的5-10元杂芳基，以及取代或未取代的3-10元杂环基； - R3和R4、R4和R5或R3和R5可能与所连接的原子一起形成取代或未取代的5-、6-或7元环； - Y4选自-N-和-N+ (O)--； - L选自键、-O-、-S-、-S(O)-、-S(O)2 -、-CR6R7 -= -NR8-、-C(O)-和-NR8C(O)-； - R6和R7各自独立地选自氢、卤素、取代或未取代的C1-8烷基、取代或未取代的3-10元杂环基、取代或未取代的C2-6烯基、取代或未取代的C2-6炔基、-CN、-OR9、-NR10R11、-S(O)R9和-S(O)2R9； - R6和R7可能与所连接的碳原子一起形成取代或未取代的C3-8环烷基或取代或未取代的3-10元杂环基； - R9选自氢、取代或未取代的C1-8烷基、取代或未取代的C2-8烯基、取代或未取代的C2-8炔基、取代或未取代的C6-10芳基、取代或未取代的5-10元杂芳基，以及取代或未取代的3-10元杂环基； - R10和R11各自独立地选自取代或未取代的C1-8烷基、取代或未取代的3-10元杂环基、取代或未取代的C6-10芳基、取代或未取代的5-10元杂芳基、取代或未取代的C2-8烯基，以及取代或未取代的C2-8炔基； - -NR10R11中的R10和R11可能与氮一起形成取代或未取代的C3-8环烷基或取代或未取代的3-10元杂环基； - R8选自氢、C(O)R12、S(O)2R12、CO2R12、取代或未取代的C1-8烷基、取代或未取代的3-10元杂环基、取代或未取代的C2-6烯基，以及取代或未取代的C2-6炔基； - R12选自取代或未取代的C1-8烷基、取代或未取代的C2-6烯基、取代或未取代的C2-6炔基、取代或未取代的3-10元杂环基、取代或未取代的C6-10芳基，以及取代或未取代的5-10元杂芳基； - Z1选自取代或未取代的C6-10芳基、取代或未取代的5-10元杂芳基、取代或未取代的3-10元杂环基，以及-NR13R14； - R13和R14各自独立地选自氢、取代或未取代的C1-8烷基、取代或未取代的C2-8烯基、取代或未取代的C2-8炔基、取代或未取代的3-10元杂环基、取代或未取代的C6-10芳基、取代或未取代的5-10元杂芳基、取代或未取代的(C1-4烷基)-(C6-10芳基)，以及取代或未取代的(C1-4烷基)-(5-10元杂芳基)； - R13和R14可能与氮一起形成取代或未取代的4-、5-、6-或7元杂环基； 其中化合物CC型被排除： 其中： - X14选自-Cl、- 、-O 、-CH3、-NHC(O) 和-CH2CH2-(苯基)； - R65选自氢、取代或未取代的C1-4烷基，以及取代或未取代的-SO2-苯基； - R60选自-NR61CH2CH2OR62、-NR61CH2CH2NR63R64，以及-NR61CH2CH2SR62； 其中： - R61选自氢和取代或未取代的苯基； - R62选自取代或未取代的苯基，以及取代或未取代的C1-4烷基； - R63和R64各自独立地选自氢、取代或未取代的C1-8烷基、取代或未取代的苯基、取代或未取代的-SO2-苯基、-C(O) 、-C(O)C(O)OH，以及-C(O)2C( )3。
• Non-lactone carbocyclic modulators of bacterial quorum sensing
  申请人：Wisconsin Alumni Research Foundation

  公开号：US10807943B2

  公开（公告）日：2020-10-20

  Non-lactone carbocyclic modulators of bacterial quorum sensing. Pharmaceutical composition containing such modulators. Methods employing such modulators for modulation of quorum sensing. Compounds are exemplified by those of formula: A-[Z]n-L1-[Y]—NH-L2-HG, where A is an optionally substituted aryl or heteroaryl group having one or two 5- or 6-member rings with up to 1-3 heteroatoms in a ring, or a substituted or unsubstituted C1-C12 acyclic aliphatic group and HG is an optionally substituted cyclopentyl group. Compounds include those where n is 1 or 0, Z is —CO—, —O—CO—, —CO—O—, —NH—CO—, —CO—NH—, —NH—CO—NH—, —O—, —S—, or —NH2, Y is —NH—CO—, —CO—CH2—C(Y1)-, or —SO2—, where Y1 is —OH, —SH, —NH2 or —F; and L1 and L2 independently are —[CH2]p1- and —[CH2]p2-, where p1 and p2, independently, are 0 or integers ranging from 1-3.

  细菌法定人数感应的非内酯碳环调节剂。含有此类调节剂的药物组合物。使用此类调节剂调节法定人数感应的方法。化合物可以式中的化合物为例： A-[Z]n-L1-[Y]—NH-L2-HG, 其中 A 是任选取代的芳基或杂芳基，该芳基或杂芳基具有一个或两个 5-或 6-成员环，环中有多达 1-3 个杂原子，或任选取代或未取代的 C1-C12 无环脂肪族基团，HG 是任选取代的环戊基。化合物包括 n 为 1 或 0，Z 为 -CO-、-O-CO-、-CO-O-、-NH-CO-、-CO-NH-、-NH-CO-NH-、-O-、-S- 或 -NH2，Y 为 -NH-CO-、-CO-CH2-C(Y1)- 或 -SO2-，其中 Y1 为 -OH、-SH、-NH2 或 -F；L1 和 L2 分别独立地为-[ ]p1-和-[ ]p2-，其中 p1 和 p2 分别独立地为 0 或 1-3 之间的整数。
• TRIAZOLYL PYRIDYL BENZENESULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS
  申请人：ChemoCentryx, Inc.

  公开号：EP2049515B1

  公开（公告）日：2011-01-26
• US9758472B2
  申请人：——

  公开号：US9758472B2

  公开（公告）日：2017-09-12
• [EN] TRIAZOLYL PYRIDYL BENZENESULFONAMIDES<br/>[FR] TRIAZOLYL PYRIDYL BENZÈNESULFONAMIDES
  申请人：CHEMOCENTRYX INC

  公开号：WO2008008375A2

  公开（公告）日：2008-01-17

  [EN] Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
  [FR] L'invention concerne des composés agissant comme antagonistes puissants du récepteur CCR2 ou CCR9. Une expérimentation sur des animaux démontre que ces composés sont utiles dans le traitement de l'inflammation, une maladie caractéristique pour CCR2 et CCR9. D'une manière générale, les composés sont des dérivés d'aryl sulfonamide et sont utiles dans des compositions pharmaceutiques, des procédés pour le traitement de maladies à médiation par CCR2, de maladies à médiation par CCR9, comme témoins dans des dosages permettant l'identification d'antagonistes de CCR2 et d'antagonistes de CCR9.